Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Template:SUIT-016"

From Bioblast
 
Line 9: Line 9:
|-
|-
| 1OctM
| 1OctM
| [[OctM]]<sub>''[[LEAK respiration]]''(n)</sub>
| [[OctM]]<sub>''[[LEAK respiration|L]]''(n)</sub>
| [[Fatty acid oxidation pathway control state| F(N)]]
| [[Fatty acid oxidation pathway control state| F(N)]]
| CETF
| CETF
Line 64: Line 64:
|-
|-
| 6Omy
| 6Omy
| [[S]]<sub>''[[LEAK respiration]]''(Omy)</sub>
| [[S]]<sub>''[[LEAK respiration|L]]''(Omy)</sub>
| [[S]]
| [[S]]
| CII
| CII

Latest revision as of 13:08, 25 November 2020

MitoPedia: SUIT

Steps and respiratory states

1OctM;2D;3G;4S;5Rot;6Omy;7U;8Ama.png


Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1OctM OctML(n) F(N) CETF 1OctM
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
  • Non-phosphorylating resting state (LEAK state); LEAK respiration L(n) in the absence of ADP, ATP, AMP (no adenylates).
2D OctMP F(N) CETF 1OctM;2D
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
3G OctGMP FN CETF&I 1OctM;2D;3G
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. & NADH-linked substrates (type N-pathway to Q).
  • Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
4S OctGMSP FNS CETF&CI&II 1OctM;2D;3G;4S
5Rot SP S CII 1OctM;2D;3G;4S;5Rot
6Omy SL(Omy) S CII 1OctM;2D;3G;4S;5Rot;6Omy
  • Succinate, S ( type S-pathway to Q).
  • Non-phosphorylating resting state (LEAK state); LEAK-respiration, L(Omy), after blocking the ATP synthase with oligomycin.
7U SE S CII 1OctM;2D;3G;4S;5Rot;6Omy;7U
8Ama ROX 1OctM;2D;3G;4S;5Rot;6Omy;7U;8Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).
Step Respiratory state Pathway control ET-Complex Comment
## AsTm AsTmE CIV CIV
## Azd CHB


Questions.jpg


Click to expand or collaps